Antibody drug conjugate experts are descending on Frankfurt in February as the European community convenes for its annual Summit. This year at the top of the agenda are issues surrounding European regulation, ADC characterisation & process development and drug safety & PK.

Through dedicated networking sessions and informative presentations, stakeholders new and old will refine how they can develop and implement a successful ADC program.